Residual Risk of Cardiovascular Disease Among Patients Treated According to Guidelines for Secondary Prevention

被引：0
|
作者：
Nichols, Gregory A.
Pedula, Kathryn L.
Wang, Fang Q.
机构：
[1] Kaiser Permanente Ctr Hlth Res, Portland, OR USA
[2] GlaxoSmithKline Inc, King Of Prussia, PA USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2009年 / 53卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A380 / A380
页数：1
相关论文
共 50 条
  • [41] PLASMA CERAMIDES IDENTIFY RESIDUAL CARDIOVASCULAR RISK IN STATIN TREATED CORONARY ARTERY DISEASE PATIENTS
    Laaksonen, R.
    Ekroos, K.
    Sysi-Aho, M.
    Vihervaara, T.
    Kauhanen, D.
    Hilvo, M.
    Hurme, R.
    Pedersen, E. Ringdal
    Tell, G.
    Nygard, O.
    ATHEROSCLEROSIS, 2016, 252 : E257 - E257
  • [42] Appraising risk of cardiovascular disease among treated hypertensives
    Sytkowski, PA
    DAgostino, RB
    Huse, DM
    Silbershatz, H
    Levy, D
    Hartz, SC
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (02) : 10547 - 10547
  • [43] Estimating Cardiovascular Risk in Spain by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice
    Jesus Amor, Antonio
    Masana, Luis
    Soriguer, Federico
    Goday, Albert
    Calle-Pascual, Alfonso
    Gaztambide, Sonia
    Rojo-Martinez, Gemma
    Valdes, Sergio
    Gomis, Ramon
    Ortega, Emilio
    REVISTA ESPANOLA DE CARDIOLOGIA, 2015, 68 (05): : 417 - 425
  • [44] Polish Forum for Prevention Guidelines on Psychosocial Cardiovascular Disease Risk Factors
    Pajak, Andrzej
    Podolec, Piotr
    Kopec, Grzegorz
    Dudek, Dominika
    Zdrojewski, Tomasz
    Drygas, Wojciech
    Undas, Anetta
    Godycki-Cwirko, Maciej
    Stanczyk, Jerzy
    Kozekl, Elzbieta
    Naruszewicz, Marek
    Opala, Grzegorz
    Czarnecka, Danuta
    Windak, Adam
    KARDIOLOGIA POLSKA, 2009, 67 (09) : 1048 - 1051
  • [45] New US prevention guidelines focus on overall risk of cardiovascular disease
    McCarthy, Michael
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 347
  • [46] Prognostic implication of residual inflammatory risk according to disease status in patients treated with percutaneous coronary intervention
    Song, H. G.
    Ahn, J. H.
    Koh, J. S.
    Bae, J. S.
    Park, Y. W.
    Hwang, S. J.
    Hwang, J. Y.
    Jeong, Y. H.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1289 - 1289
  • [47] Quantifying the residual risk of cardiovascular events in secondary prevention patients with uncontrolled LDL-C receiving statins
    Nasir, K.
    Mallya, U. G.
    Delea, T. E.
    Kuznik, A.
    Klimchak, A.
    Briggs, A.
    Joulain, F.
    EUROPEAN HEART JOURNAL, 2016, 37 : 63 - 63
  • [48] Underuse of statins for secondary prevention of atherosclerotic cardiovascular disease events among ambulatory surgical patients
    Schonberger, Robert B.
    Vallurupalli, Vivek
    Matlin, Hollie
    Blitz, Daina
    Nwozuzu, Adambeke
    Barron, Brian
    Zhang, Yuemei
    Dai, Feng
    Jacoby, Daniel
    Nasir, Khurram
    Bardia, Amit
    PREVENTIVE MEDICINE REPORTS, 2020, 18
  • [49] The Problem With Cardiovascular Disease Prevention Guidelines
    Jay N. Cohn
    Daniel A. Duprez
    Current Treatment Options in Cardiovascular Medicine, 2012, 14 (6) : 571 - 574
  • [50] ECONOMIC EVALUATION OF ROSUVASTATIN VERSUS ATORVASTATIN, SIMVASTATIN AND PRAVASTATIN IN HIGH RISK PATIENTS TREATED FOR PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN GREECE
    Fragoulakis, V
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2011, 14 (07) : A378 - A378
12345